Risk factors for CAR‐T cell manufacturing failure among DLBCL patients: A nationwide survey in Japan

Risk factors for CAR‐T cell manufacturing failure among DLBCL patients: A nationwide survey in Japan

Summary For successful chimeric antigen receptor T (CAR‐T) cell therapy, CAR‐T cells must be manufactured without failure caused by suboptimal expansion. In order to determine risk factors for CAR‐T cell manufacturing failure, we performed a nationwide cohort study in Japan and analysed patients wit...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:British journal of haematology 2023-07, Vol.202 (2), p.256-266
Hauptverfasser: Jo, Tomoyasu, Yoshihara, Satoshi, Okuyama, Yoshiki, Fujii, Keiko, Henzan, Tomoko, Kahata, Kaoru, Yamazaki, Rie, Takeda, Wataru, Umezawa, Yoshihiro, Fukushima, Kentaro, Ashida, Takashi, Yamada‐Fujiwara, Minami, Hanajiri, Ryo, Yonetani, Noboru, Tada, Yuma, Shimura, Yuji, Nishikii, Hidekazu, Shiba, Norio, Mimura, Naoya, Ando, Jun, Sato, Takayuki, Nakashima, Yasuhiro, Ikemoto, Junko, Iwaki, Keita, Fujiwara, Shin‐ichiro, Ri, Masaki, Nagamura‐Inoue, Tokiko, Tanosaki, Ryuji, Arai, Yasuyuki
Format: Artikel
Sprache:eng
Schlagworte:
Apheresis
Bendamustine Hydrochloride - therapeutic use
CD4 antigen
CD8 antigen
Cell therapy
chimeric antigen receptor T cell therapy
Chimeric antigen receptors
Cohort Studies
Failure
Hematology
Humans
Immunotherapy, Adoptive
Japan - epidemiology
Lymphocytes
Lymphocytes T
Lymphoma
Lymphoma, Large B-Cell, Diffuse - drug therapy
Manufacturing
manufacturing failure
Multivariate analysis
Peripheral blood
Platelets
Receptors, Antigen, T-Cell - therapeutic use
Receptors, Chimeric Antigen - therapeutic use
Risk Factors
T-Lymphocytes
tisagenlecleucel
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Summary For successful chimeric antigen receptor T (CAR‐T) cell therapy, CAR‐T cells must be manufactured without failure caused by suboptimal expansion. In order to determine risk factors for CAR‐T cell manufacturing failure, we performed a nationwide cohort study in Japan and analysed patients with diffuse large B‐cell lymphoma (DLBCL) who underwent tisagenlecleucel production. We compared clinical factors between 30 cases that failed (7.4%) with those that succeeded (n = 378). Among the failures, the proportion of patients previously treated with bendamustine (43.3% vs. 14.8%; p 
ISSN:0007-1048
1365-2141
DOI:10.1111/bjh.18831